This study aims to comprehensively assess the existing controlled trials on SGLT-2 inhibitor therapy for HF and T2DM patients through a meta-analysis approach, aiming to clarify their efficacy and safety, and ultimately provide more comprehensive and scientific evidence to support the treatment of HF and T2DM patients. Here, SLC5A2 is linked to hydrops fetalis.